Crescent Biopharma (CBIO) Restructuring Costs (2024)
Crescent Biopharma (CBIO) posted quarterly Restructuring Costs of $2.0 million for Q4 2024, down 63.4% quarter-over-quarter from $5.5 million in Q3 2024.
Crescent Biopharma (CBIO) Restructuring Costs (2024) Analysis & Trends
Crescent Biopharma (CBIO) has reported Restructuring Costs for 1 consecutive years, with $2.0 million the latest figure, recorded in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.02 Mn |
| Sep 30, 2024 | 5.51 Mn |